- Report reflects Seagen’s Passion for Patients + Sustainable Innovation - Overview of ESG priorities, achievements, and future commitments -
Submitted by Seagen
BOTHELL, Wash., December 7, 2021 /CSRwire/ - As a demonstration of its long-term environmental, social, and governance (ESG) commitments, Seagen Inc. (Nasdaq:SGEN) today announced the release of its inaugural Corporate Responsibility Report. The report highlights Seagen’s dedication to patients, innovative science, transformative therapies, and how the company aims to operate in a sustainable manner. Available online at www.seagen.com, the report features employee insights, case studies, and the company’s accomplishments and future areas of focus.
“Seagen is a multi-product oncology company with operations in the United States, Canada and across Europe, enabling us to meet the needs of a wide range of people living with cancer,” said Clay Siegall, Ph.D., President, Chief Executive Officer, and Chairman of the Board at Seagen. “This report reflects our core values and dedication to our mission of developing innovative cancer therapies, while operating in a responsible manner as we continue to grow and expand our business.”
Seagen’s report Passion for Patients + Sustainable Innovation reflects the deep-rooted commitment and relentless drive to help patients around the world. Seagen’s Corporate Responsibility strategy and ESG disclosures are organized into four pillars: Innovation for a Sustainable Future, Patient & Community Care, Employee Empowerment, and Responsible Stewardship.
Key highlights detailed in the Corporate Responsibility report include:
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Seagen Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen’s commitments, expectations, goals, and aspirations regarding ESG, corporate responsibility, sustainability, environmental, employee, and business matters. Forward-looking statements are aspirational and based on Seagen management’s beliefs and assumptions and on information currently available to them. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Such statements may be based on standards for measuring progress that are still developing, internal controls and process that continue to evolve, and assumptions that are subject to change in the future. Forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Vice President, Corporate Communications
Senior Vice President, Investor Relations
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
More from Seagen